Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Should Cannabis Be Given at Night or During the Day for Dementia Care? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Many families exploring medical cannabis for dementia symptoms ask whether it is best taken in the morning or at night. The answer depends largely on the symptoms being targeted, the formulation used (THC or CBD dominant), and how an individual with dementia responds to cannabinoids. 

According to NHS guidance, cannabis-based medicinal products (CBMPs) can only be prescribed by specialist doctors for certain conditions such as epilepsy, multiple sclerosis, or chemotherapy-related nausea not for dementia. However, studies continue to explore how cannabinoids might affect sleep, agitation, and daytime alertness in people living with dementia. 

Can medical cannabis be accessed legally for women’s health?

What The Research Suggests 

Clinical studies reviewed in Frontiers in Medicine (Hermush et al., 2022) and PMC (Outen et al., 2021) suggest that CBD-dominant oils may reduce anxiety or restlessness without strong sedative effects, making them more suitable for daytime use. Conversely, formulations containing THC tend to cause drowsiness and may be better tolerated when given in the evening to help with agitation or disturbed sleep. 

However, both studies emphasise that results are inconsistent and highly individual. No standard timing or dosage guidance exists for dementia, and all administration should be supervised by a clinician. 

NICE guidance on cannabis-based medicinal products (NG144, 2025) (NICE NG144) and the Alzheimer’s Society UK (Cannabis, CBD oil and dementia) both note that there is currently insufficient evidence to recommend cannabis for dementia symptoms at any time of day. 

Clinical Bottom Line 

  • There is no official recommendation on giving cannabis during the day or at night for dementia care. 
  • CBD-dominant formulations may be better suited to daytime use due to mild, non-sedating effects. 
  • THC-containing products may cause drowsiness and be used in the evening under close supervision. 
  • NICE and NHS do not currently endorse cannabis for dementia symptoms except in research settings. 
  • Timing and dosage should be individualised and managed by a specialist prescriber. 

About AlleviMed 

AlleviMed offers educational guidance on how medical cannabis eligibility is assessed within UK regulations. It helps patients and professionals understand the legal and clinical pathways for specialist prescribing, promoting safety and regulatory awareness rather than product use. 

Takeaway 

The timing of cannabis administration in dementia care should always depend on individual response and clinical supervision. While some evidence suggests THC may aid evening rest and CBD may support daytime calm, no formal recommendations exist. Both NICE and the NHS stress that medical cannabis is not approved for dementia outside research trials. Anyone considering its use should seek advice from a qualified specialist and avoid unregulated products. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories